A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain

OBJECTIVE: This study evaluated the efficacy and safety of oral naldemedine 0.1 mg, 0.2 mg, or 0.4 mg once daily in patients who had opioid-induced constipation (OIC) and maintained a stable laxative regimen. METHODS: This four-week, phase 2b, randomized, double-blind placebo-controlled trial (clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Webster, Lynn R, Yamada, Tadaaki, Arjona Ferreira, Juan Camilo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
OPIOIDS & SUBSTANCE USE DISORDERS SECTION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914456/
https://www.ncbi.nlm.nih.gov/pubmed/28371937
http://dx.doi.org/10.1093/pm/pnw325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914456/
https://www.ncbi.nlm.nih.gov/pubmed/28371937
http://dx.doi.org/10.1093/pm/pnw325

Ejemplares similares